{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:28:02Z","timestamp":1754159282613,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Targeted therapies for anaplastic lymphoma kinase (<jats:italic>ALK<\/jats:italic>) mutations in non-small cell lung cancer (NSCLC) generally extend survival and alleviate symptoms. However, significant tumor reduction or complete remission remains rare. We report a rare case of a 14-year-old girl, whose father and grandfather both had lung cancer, diagnosed with advanced, multi-site metastatic <jats:italic>ALK<\/jats:italic>-positive NSCLC. She was treated with Iruplinalkib, a newly approved targeted therapy in China, resulting in remarkable tumor shrinkage. The patient presented with severe symptoms, including persistent cough, pain, and hemoptysis. A lung CT scan revealed a large mass, which was pathologically diagnosed as pulmonary adenocarcinoma. After initiating Iruplinalkib therapy, the primary tumor rapidly decreased in size by 80.3%, from 132 mm \u00d7 97 mm to 26 mm \u00d7 21 mm, within one month. Most metastatic lesions also showed significant regression. By six months, the pulmonary tumor had almost disappeared. This case underscores the potential of Iruplinalkib, which is currently not available outside of China, to induce rapid and profound tumor regression in <jats:italic>ALK<\/jats:italic>-positive NSCLC, particularly in adolescent patients with aggressive clinical presentations. We hope that the anticancer efficacy of Iruplinalkib will be recognized globally and that it will become accessible to <jats:italic>ALK<\/jats:italic>-positive lung cancer patients worldwide.<\/jats:p>","DOI":"10.3389\/fonc.2025.1645580","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T04:10:41Z","timestamp":1753416641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Remarkable tumor response to Iruplinalkib in a 14-year-old girl with ALK-positive advanced metastatic non\u2013small-cell lung cancer: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiahao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingdi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuojuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongsheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103099","article-title":"Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial","volume":"81","author":"Xia","year":"2025","journal-title":"J eClinicalMedicine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"J CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9080107","article-title":"ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice","volume":"9","author":"Hofman","year":"2017","journal-title":"J Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0488","article-title":"ALK fusions in a wide variety of tumor types respond to anti-ALK targeted therapy","volume":"22","author":"Ross","year":"2017","journal-title":"J Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13348","article-title":"Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer","volume":"17","author":"Wang","year":"2023","journal-title":"J Mol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.916315","article-title":"Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases","volume":"2022","author":"Liao","year":"2022","journal-title":"J Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01970-w","article-title":"Iruplinalkib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"J Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104776","article-title":"Cancer in a drop: Advances in liquid biopsy in 2024","volume":"2025","author":"Borea","year":"2025","journal-title":"J Crit Rev Oncol Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.02.004","article-title":"Iruplinalkib (WX-0593), the seventh ALK tyrosine kinase inhibitor approved in people\u2019s republic of China with more to come","volume":"19","author":"Li","year":"2024","journal-title":"J J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41392-021-00841-8","article-title":"Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial","volume":"7","author":"Shi","year":"2022","journal-title":"J Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9073","article-title":"A phase II trial of ALK\/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non\u2013small cell lung cancer","volume":"2022","author":"Shi","year":"2022","journal-title":"J Lung Cancer\u2014Non-Small Cell Metastatic"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1645580\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T04:10:42Z","timestamp":1753416642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1645580\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":12,"alternative-id":["10.3389\/fonc.2025.1645580"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1645580","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"1645580"}}